![\"\"\/](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/09\/GettyImages-2162809200-430x241.jpg\")
<\/p>\n <\/p>\n
The World Health Organisation (WHO) has added key obesity and type 2 diabetes (T2D) medications semaglutide, tirzepatide, liraglutide and dulaglutide to its essential medicines list (EML). Image credit: Alones Creative, IStock\/Getty Images Plus via Getty Images.<\/p>\n
The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity<\/a> and type 2 diabetes (T2D)<\/a> drugs.<\/p>\n This includes Novo Nordisk\u2019s semaglutide, marketed as Ozempic and Wegovy for T2D and weight management, respectively, as well as Eli Lilly\u2019s tirzepatide, marketed as Mounjaro and Zepbound, again in T2D and weight management, respectively.<\/p>\n \n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n The United Nations (UN) agency has added the glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1\/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists to the EML following a review from the WHO Expert Committee, which found \u201cstrong scientific evidence\u201d to support their benefits in patients with T2D.<\/p>\n However, WHO raised concerns about the costs of both semaglutide and tirzepatide, which come with a hefty price tag of between $997 and $1349 for a one-month prescription in the US, which the agency warns could complicate patient accessibility.<\/p>\n Both Lilly\u2019s Trulicity (dulaglutide) and Novo Nordisk\u2019s Saxenda (liraglutide) are also on the list. Saxenda is currently very similar in price to its more efficacious successor, semaglutide. Meanwhile, Trulicity also offers only a small price reduction, being sold at $987 instead of the $1079.77 charge for Mounjaro.<\/p>\n To promote accessibility to these drugs for all patients worldwide, the WHO has called for their uptake in global primary care systems, while encouraging the development of cheaper generic alternatives to drive down costs.<\/p>\n \u201cThis designation is likely to transform the overall obesity, diabetes and cardiovascular disease market by increasing demand, driving price reductions via generic competition, and expanding usage beyond affluent populations,\u201d said Valentina Gburcik, senior director of cardiovascular and metabolic disorders at GlobalData.<\/p>\n Gburcik also noted that the move could \u201cshift market focus toward broader primary care indications rather than niche or elite populations\u201d, while it may also encourage pharmaceutical manufacturers to accelerate global regulatory approvals and distribution efforts.<\/p>\n Generics to improve GLP-1RA accessibility<\/p>\n The August 2025 US approval of Teva Pharmaceutical\u2019s generic Saxenda has left Novo Nordisk\u2019s version vulnerable to competition.<\/p>\n According to Gburcik, liraglutide\u2019s EML listing will \u201conly accelerate Saxenda\u2019s market share erosion by stimulating generic manufacturing,\u201d though the move could also potentially \u201cincrease total sales volume at lower prices\u201d.<\/p>\n This has led analysts at GlobalData, parent company of Pharmaceutical Technology, to forecast that Saxenda will make just $135m in 2031 \u2013 down 91% from the $1.5bn sales seen at its peak in 2022.<\/p>\n Meanwhile, semaglutide\u2019s patent expiry is set to be another thorn in Novo Nordisk\u2019s side, as the Danish pharma\u2019s best-selling drug will face generic competition in 2026 in India, China, Brazil, Canada and Turkey.<\/p>\n Though its patent in the key US market is not due to expire until the early 2030s, generics will soon be permitted in these markets. Chinese drug manufacturers<\/a> are now looking to jump on the GLP-1RA bandwagon, preparing their semaglutide generics ready for next year\u2019s patent cliff.<\/p>\n Semaglutide\u2019s global sales stood at DKr178.2bn ($28bn) in 2024.<\/p>\n Eli Lilly\u2019s Trulicity patent is set to expire in 2027, while the patent for the tirzepatide\u202fmolecule will expire in 2036 in the US, but active formulation patents may extend the exclusivity for Eli Lilly\u2019s Mounjaro and Zepbound until around 2039.<\/p>\n \n Sign up for our daily news round-up! Pharmaceutical Technology Excellence Awards – The Benefits of Entering<\/p>\n Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards<\/strong><\/a> celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don\u2019t miss your chance to stand out\u2014submit your entry today!<\/p>\n![\"\"\/](\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/GMS-logo.svg\"){kind=logo}
Discover B2B Marketing That Performs <\/p>\n
\n\t\t\t\t\t\t\tFind out more <\/a><\/p>\n![\"Email](\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/newsletter-new.svg\")
<\/p>\n
\n Give your business an edge with our leading industry insights.\n <\/p>\n